Suvorexant (dual orexin receptor antagonist)

DRUG2 trials

Sponsors

Johns Hopkins University, Marianne Goodman

Conditions

Major Depressive Disorder (MDD)Opioid Use DisorderStimulant Use DisorderSuicide Risk

Phase 2

Suvorexant for Opioid/Stimulant Co-use

CompletedNCT05546515

Johns Hopkins UniversityOpioid Use Disorder, Stimulant Use Disorder

Start: 2022-12-01End: 2024-11-30Updated: 2025-12-23

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

RecruitingNCT06854224

Marianne GoodmanMajor Depressive Disorder (MDD), Suicide Risk

Start: 2025-09-01End: 2027-07-01Target: 30Updated: 2025-09-25